Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Current Pharmaceutical Biotechnology
|
December 16, 2006
Thalidomide in multiple myeloma
T M Moehler, J Hillengass, A Glasmacher, et al.
Critical Reviews in Oncology/Hematology
|
March 14, 2003
Angiogenesis in hematologic malignancies
T M Moehler, A D Ho, H Goldschmidt, et al.
Annals of Hematology
|
January 18, 2002
Angiogenesis in hematologic malignancies
T M Moehler, K Neben, A D Ho, et al.
Current Pharmaceutical Design
|
April 14, 2004
Antiangiogenic therapy in hematologic malignancies
T M Moehler, J Hillengass, H Goldschmidt, et al.
International Journal of Hematology
|
October 11, 2008
Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis
J Hillengass, A D Ho, H Goldschmidt, et al.
Blood
|
December 12, 2001
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
T M Moehler, K Neben, A Benner, et al.
Der Radiologe
|
September 28, 2000
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]
T M Moehler, H Hawighorst, K Neben, et al.
International Journal of Cancer
|
August 24, 2001
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging
T M Moehler, H Hawighorst, K Neben, et al.
International Journal of Hematology
|
March 5, 2008
Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products
S Schmitt, V Mailaender, G Egerer, et al.
European Radiology
|
November 1, 2014
The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken
J Hillengass, J Stoll, C M Zechmann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Current Pharmaceutical Biotechnology
|
December 16, 2006
Thalidomide in multiple myeloma
T M Moehler, J Hillengass, A Glasmacher, et al.
Critical Reviews in Oncology/Hematology
|
March 14, 2003
Angiogenesis in hematologic malignancies
T M Moehler, A D Ho, H Goldschmidt, et al.
Annals of Hematology
|
January 18, 2002
Angiogenesis in hematologic malignancies
T M Moehler, K Neben, A D Ho, et al.
Current Pharmaceutical Design
|
April 14, 2004
Antiangiogenic therapy in hematologic malignancies
T M Moehler, J Hillengass, H Goldschmidt, et al.
International Journal of Hematology
|
October 11, 2008
Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis
J Hillengass, A D Ho, H Goldschmidt, et al.
Blood
|
December 12, 2001
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
T M Moehler, K Neben, A Benner, et al.
Der Radiologe
|
September 28, 2000
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]
T M Moehler, H Hawighorst, K Neben, et al.
International Journal of Cancer
|
August 24, 2001
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging
T M Moehler, H Hawighorst, K Neben, et al.
International Journal of Hematology
|
March 5, 2008
Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products
S Schmitt, V Mailaender, G Egerer, et al.
European Radiology
|
November 1, 2014
The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken
J Hillengass, J Stoll, C M Zechmann, et al.
Page
of 2